Correction to: Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy (Drug Safety, (2021), 44, 10, (1109-1119), 10.1007/s40264-021-01107-6)

John W. Day, Jerry R. Mendell, Eugenio Mercuri, Richard S. Finkel, Kevin A. Strauss, Aaron Kleyn, Sitra Tauscher-Wisniewski, Francis Fonyuy Tukov, Sandra P. Reyna, Deepa H. Chand

Research output: Contribution to journalComment/debate

1 Scopus citations

Abstract

In the original publication of the article, footnote marker ‘b’ was incorrectly placed in rows 2 and 3 of Table 4. The correct Table 4 is published here.

Original languageEnglish
Pages (from-to)191-192
Number of pages2
JournalDrug Safety
Volume45
Issue number2
DOIs
StatePublished - Feb 2022

Fingerprint

Dive into the research topics of 'Correction to: Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy (Drug Safety, (2021), 44, 10, (1109-1119), 10.1007/s40264-021-01107-6)'. Together they form a unique fingerprint.

Cite this